The 340B Drug Pricing Program requires pharmaceutical manufacturers to provide hospitals and clinics with discounted drugs at 20–50% below average wholesale prices, but **the program does not require these discounts to be passed to patients**, and research shows virtually no patients receive cost reductions at the pharmacy counter. Despite distributing $81.4 billion in discounted drugs in 2024, the program primarily benefits hospitals' operational budgets rather than individual patient bills. Hospitals and clinics participating in the 340B program keep complete discretion over how—or whether—to use savings. For most insured patients, the structure of copays and drug pricing means the hospital's discount yields no out-of-pocket savings at all.
Table of Contents
- How 340B Works and Who the Discounts Actually Reach
- Why Insured Patients See No Discount
- Where the 340B Savings Actually Go
- Limited Patient Benefits and Medicare Carve-Out
- Why Oversight Is Weak and Congress Is Moving
How 340B Works and Who the Discounts Actually Reach
The 340B program, enacted in 1992, allows hospitals, clinics, and other healthcare entities certified by the Health Resources and Services Administration (HRSA) to purchase certain outpatient drugs at steep manufacturer discounts. Participating entities—primarily safety-net hospitals serving uninsured and low-income populations—then resell these drugs to their patients, theoretically retaining the difference.
HRSA explains that the program requires manufacturers to offer these discounts, but imposes no guardrails on how entities use the savings. However, a 2011 Government Accountability Office audit of 55 covered entities found that only 30 entities (55%) provided any 340B discount to low-income or uninsured patients, and only 23 entities (42% of all audited) passed the full discount through. That means nearly half the audited entities kept all the savings for themselves, with no requirement to account for how those dollars were spent.
Why Insured Patients See No Discount
If you have health insurance, the 340B program almost certainly does not lower your pharmacy bill. Insured patients pay copays calculated on the drug's list price, not the 340B-discounted price the hospital purchased it at. Your copay is set by your insurance plan and does not change if your hospital negotiated a bigger discount.
This structural gap means the majority of hospitals' patients—those with commercial insurance—receive zero benefit from the program. A hospital might buy a drug at a 40% discount and still charge insured patients the same copay as any other pharmacy, pocketing the entire savings.
Where the 340B Savings Actually Go
Research analyzing pharmacy claims data across the U.S. found that virtually no patients using cash, insurance, or Medicare received 340B discounts on their copays. The savings flow to hospital budgets instead. One comparison illustrates the gap: Disproportionate Share Hospitals (DSHs)—the safety-net hospitals most associated with charity care—received $44 billion in 340B discounts in 2022 but provided only $18.5 billion in charity care. The majority of 340B savings are retained for operational costs, facility improvements, or other hospital expenses rather than returned to patients.
Limited Patient Benefits and Medicare Carve-Out
The one documented exception is narrow: a 2018 CMS policy gave Medicare beneficiaries receiving 340B-acquired drugs at hospital outpatient departments coinsurance reductions, generating an estimated $320 million in patient savings in that year alone. However, this benefit applies only to Medicare beneficiaries at hospital outpatient departments, not to other populations or retail pharmacies. Some uninsured and low-income patients may benefit if their hospital has chosen to pass discounts through, but there is no transparent way to know. Federal oversight is minimal, entities are not required to report how they deploy 340B savings, and no central database tracks whether a specific hospital passes discounts to patients.
Why Oversight Is Weak and Congress Is Moving
Federal oversight of how entities use 340B savings is minimal. HRSA conducted only 144 audits of covered entities in fiscal 2024—compared to just 5 audits of manufacturers—and entities are not required to report how they use the savings. Without systematic accounting, there is no way to know whether discounts fund patient care, charity programs, or entity operations.
This accountability gap prompted Congress to act. The 340B Access Act, introduced in 2025, proposes requiring entities to demonstrate patient benefit from 340B discounts and mandating transparency on how savings are used—provisions that would be unnecessary if patient cost-reduction was already occurring systematically.